These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36481598)

  • 1. Structure based design and evaluation of benzoheterocycle derivatives as potential dual HIV-1 protease and reverse transcriptase inhibitors.
    Zhu M; Shan Q; Ma L; Dong B; Wang J; Zhang G; Wang M; Zhou J; Cen S; Wang Y
    Eur J Med Chem; 2023 Jan; 246():114981. PubMed ID: 36481598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase.
    Zhu M; Shan Q; Ma L; Wen J; Dong B; Zhang G; Wang M; Wang J; Zhou J; Cen S; Wang Y
    Eur J Med Chem; 2021 Aug; 220():113498. PubMed ID: 33933756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
    Zhu M; Ma L; Wen J; Dong B; Wang Y; Wang Z; Zhou J; Zhang G; Wang J; Guo Y; Liang C; Cen S; Wang Y
    Eur J Med Chem; 2020 Jan; 186():111900. PubMed ID: 31771827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fullerene derivatives as dual inhibitors of HIV-1 reverse transcriptase and protease.
    Yasuno T; Ohe T; Kataoka H; Hashimoto K; Ishikawa Y; Furukawa K; Tateishi Y; Kobayashi T; Takahashi K; Nakamura S; Mashino T
    Bioorg Med Chem Lett; 2021 Jan; 31():127675. PubMed ID: 33161121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors.
    Olomola TO; Klein R; Mautsa N; Sayed Y; Kaye PT
    Bioorg Med Chem; 2013 Apr; 21(7):1964-71. PubMed ID: 23415084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural mechanisms of HIV drug resistance.
    Erickson JW; Burt SK
    Annu Rev Pharmacol Toxicol; 1996; 36():545-71. PubMed ID: 8725401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active site binding modes of dimeric phloroglucinols for HIV-1 reverse transcriptase, protease and integrase.
    Gupta P; Kumar R; Garg P; Singh IP
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4427-31. PubMed ID: 20594846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genotypic antiretroviral resistance testing and phylogenetic analysis of protease and reverse transcriptase in antiretroviral drug-naïve AIDS patients in Henan province].
    Yang K; Li JY; Bao ZY; Li HP; Li L; Zhuang DM; Wang Z; Li H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2005 May; 26(5):351-5. PubMed ID: 16053762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 drug resistance in newly infected individuals.
    Boden D; Hurley A; Zhang L; Cao Y; Guo Y; Jones E; Tsay J; Ip J; Farthing C; Limoli K; Parkin N; Markowitz M
    JAMA; 1999 Sep 22-29; 282(12):1135-41. PubMed ID: 10501116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase.
    Gu SX; Xue P; Ju XL; Zhu YY
    Bioorg Med Chem; 2016 Nov; 24(21):5007-5016. PubMed ID: 27658796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco.
    Bakhouch K; Oulad-Lahcen A; Bensghir R; Blaghen M; Elfilali KM; Ezzikouri S; Abidi O; Hassar M; Wakrim L
    J Infect Dev Ctries; 2009 Jun; 3(5):380-91. PubMed ID: 19759509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel pyridinium-type fullerene derivatives as multitargeting inhibitors of HIV-1 reverse transcriptase, HIV-1 protease, and HCV NS5B polymerase.
    Kobayashi T; Yasuno T; Takahashi K; Nakamura S; Mashino T; Ohe T
    Bioorg Med Chem Lett; 2021 Oct; 49():128267. PubMed ID: 34271071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetra-chloro-(bis-(3,5-dimethylpyrazolyl)methane)gold(III) chloride: An HIV-1 reverse transcriptase and protease inhibitor.
    Fonteh PN; Keter FK; Meyer D; Guzei IA; Darkwa J
    J Inorg Biochem; 2009 Feb; 103(2):190-4. PubMed ID: 19019450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients.
    Birk M; Sönnerborg A
    AIDS; 1998 Dec; 12(18):2369-75. PubMed ID: 9875574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HIV/SIV activity of icariin and its metabolite anhydroicaritin mainly involve reverse transcriptase.
    Xie Y; Xie L; Chen A; Wu S; Mo Y; Guo X; Zeng C; Huang X; He J
    Eur J Pharmacol; 2020 Oct; 884():173327. PubMed ID: 32726656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of anti-HIV double-drugs. conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor through spontaneously cleavable linkers.
    Matsumoto H; Kimura T; Hamawaki T; Kumagai A; Goto T; Sano K; Hayashi Y; Kiso Y
    Bioorg Med Chem; 2001 Jun; 9(6):1589-600. PubMed ID: 11408178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
    Wirden M; Delaugerre C; Marcelin AG; Ktorza N; Ait Mohand H; Dominguez S; Schneider L; Ghosn J; Pauchard M; Costagliola D; Katlama C; Calvez V
    Antimicrob Agents Chemother; 2004 Feb; 48(2):644-7. PubMed ID: 14742228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors.
    Imamichi T
    Curr Pharm Des; 2004; 10(32):4039-53. PubMed ID: 15579086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced antiretroviral drug susceptibility among patients with primary HIV infection.
    Little SJ; Daar ES; D'Aquila RT; Keiser PH; Connick E; Whitcomb JM; Hellmann NS; Petropoulos CJ; Sutton L; Pitt JA; Rosenberg ES; Koup RA; Walker BD; Richman DD
    JAMA; 1999 Sep 22-29; 282(12):1142-9. PubMed ID: 10501117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.